{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:59:18Z","timestamp":1769122758650,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T00:00:00Z","timestamp":1438560000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T00:00:00Z","timestamp":1438560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/aps.2015.42","type":"journal-article","created":{"date-parts":[[2015,8,3]],"date-time":"2015-08-03T09:01:08Z","timestamp":1438592468000},"page":"1085-1098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro"],"prefix":"10.1038","volume":"36","author":[{"given":"Han","family":"Qiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-ming","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-guo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-ting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,3]]},"reference":[{"key":"BFaps201542_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88: 1082\u201390.","journal-title":"Cancer"},{"key":"BFaps201542_CR2","first-page":"931","volume":"93","author":"AA Rose","year":"2006","unstructured":"Rose AA, Siegel PM . Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 2006; 93: 931\u201343.","journal-title":"Bull Cancer"},{"key":"BFaps201542_CR3","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1172\/JCI114100","volume":"83","author":"DE Hughes","year":"1989","unstructured":"Hughes DE, MacDonald BR, Russell RG, Gowen M . Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83: 1930\u20135.","journal-title":"J Clin Invest"},{"key":"BFaps201542_CR4","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1172\/JCI116422","volume":"91","author":"M Sahni","year":"1993","unstructured":"Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ . Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91: 2004\u201311.","journal-title":"J Clin Invest"},{"key":"BFaps201542_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1172\/JCI114459","volume":"85","author":"A Carano","year":"1990","unstructured":"Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC . Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990; 85: 456\u201361.","journal-title":"J Clin Invest"},{"key":"BFaps201542_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","volume":"17","author":"H Murakami","year":"1995","unstructured":"Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17: 137\u201344.","journal-title":"Bone"},{"key":"BFaps201542_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S8756-3282(96)00184-6","volume":"19","author":"X Yu","year":"1996","unstructured":"Yu X, Scholler J, Foged NT . Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 1996; 19: 339\u201345.","journal-title":"Bone"},{"key":"BFaps201542_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/j.1582-4934.2012.01527.x","volume":"16","author":"L Insalaco","year":"2012","unstructured":"Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, et al. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med 2012; 16: 2186\u201395.","journal-title":"J Cell Mol Med"},{"key":"BFaps201542_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126\u201334.","journal-title":"Br J Cancer"},{"key":"BFaps201542_CR10","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","volume":"15","author":"O Fromigue","year":"2000","unstructured":"Fromigue O, Lagneaux L, Body JJ . Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15: 2211\u201321.","journal-title":"J Bone Miner Res"},{"key":"BFaps201542_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ijc.28965","volume":"137","author":"A Mathew","year":"2015","unstructured":"Mathew A, Brufsky A . Bisphosphonates in breast cancer. Int J Cancer 2015; 137: 753\u201364.","journal-title":"Int J Cancer"},{"key":"BFaps201542_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.biopha.2013.04.006","volume":"67","author":"HD Kiper","year":"2013","unstructured":"Kiper HD, Tezcanli Kaymaz B, Gokbulut AA, Selvi N, Avci CB, Kosova B, et al. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomed Pharmacother 2013; 67: 527\u201332.","journal-title":"Biomed Pharmacother"},{"key":"BFaps201542_CR13","doi-asserted-by":"publisher","first-page":"11913","DOI":"10.1007\/s13277-014-2460-5","volume":"35","author":"IT Wang","year":"2014","unstructured":"Wang IT, Chou SC, Lin YC . Zoledronic acid induces apoptosis and autophagy in cervical cancer cells. Tumour Biol 2014; 35: 11913\u201320.","journal-title":"Tumour Biol"},{"key":"BFaps201542_CR14","doi-asserted-by":"publisher","first-page":"e101207","DOI":"10.1371\/journal.pone.0101207","volume":"9","author":"XY Ge","year":"2014","unstructured":"Ge XY, Yang LQ, Jiang Y, Yang WW, Fu J, Li SL . Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. PLoS One 2014; 9: e101207.","journal-title":"PLoS One"},{"key":"BFaps201542_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","volume":"96","author":"N Horie","year":"2007","unstructured":"Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, et al. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 2007; 96: 255\u201361.","journal-title":"Br J Cancer"},{"key":"BFaps201542_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3892\/ijo.2013.1809","volume":"42","author":"T Ibrahim","year":"2013","unstructured":"Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, et al. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol 2013; 42: 1263\u201370.","journal-title":"Int J Oncol"},{"key":"BFaps201542_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00432-014-1882-1","volume":"141","author":"KW Luo","year":"2015","unstructured":"Luo KW, Ko CH, Yue GG, Gao S, Lee JK, Li G, et al. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model. J Cancer Res Clin Oncol 2015; 141: 1025\u201336.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFaps201542_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","volume":"257","author":"V Stresing","year":"2007","unstructured":"Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P . Bisphosphonates in cancer therapy. Cancer Lett 2007; 257: 16\u201335.","journal-title":"Cancer Lett"},{"key":"BFaps201542_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3892\/or.2013.2907","volume":"31","author":"MP Dos Santos","year":"2014","unstructured":"Dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL . In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol Rep 2014; 31: 955\u201368.","journal-title":"Oncol Rep"},{"key":"BFaps201542_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/abbs\/gmu069","volume":"46","author":"Y Yu","year":"2014","unstructured":"Yu Y, Song Z, Yang S, Yang X, Zhang J, Lu S . Everolimus and zoledronic acid \u2014 a potential synergistic treatment for lung adenocarcinoma bone metastasis. Acta Biochim Biophys Sin 2014; 46: 792\u2013801.","journal-title":"Acta Biochim Biophys Sin"},{"key":"BFaps201542_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1590\/S0074-02762003000700017","volume":"98","author":"SR de Paiva","year":"2003","unstructured":"de Paiva SR, Figueiredo MR, Aragao TV, Kaplan MA . Antimicrobial activity in vitro of plumbagin isolated from Plumbago species. Mem Inst Oswaldo Cruz 2003; 98: 959\u201361.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"BFaps201542_CR22","first-page":"10","volume":"35","author":"I Sharma","year":"1991","unstructured":"Sharma I, Gusain D, Dixit VP . Hypolipidaemic and antiatherosclerotic effects of plumbagin in rabbits. Indian J Physiol Pharmacol 1991; 35: 10\u20134.","journal-title":"Indian J Physiol Pharmacol"},{"key":"BFaps201542_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.intimp.2009.03.022","volume":"9","author":"R Checker","year":"2009","unstructured":"Checker R, Sharma D, Sandur SK, Khanam S, Poduval TB . Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-kappaB activation in lymphocytes. Int Immunopharmacol 2009; 9: 949\u201358.","journal-title":"Int Immunopharmacol"},{"key":"BFaps201542_CR24","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.1158\/0008-5472.CAN-08-2494","volume":"68","author":"MH Aziz","year":"2008","unstructured":"Aziz MH, Dreckschmidt NE, Verma AK . Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008; 68: 9024\u201332.","journal-title":"Cancer Res"},{"key":"BFaps201542_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/carcin\/bgr249","volume":"33","author":"JM Sand","year":"2012","unstructured":"Sand JM, Bin Hafeez B, Jamal MS, Witkowsky O, Siebers EM, Fischer J, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), isolated from Plumbago zeylanica, inhibits ultraviolet radiation-induced development of squamous cell carcinomas. Carcinogenesis 2012; 33: 184\u201390.","journal-title":"Carcinogenesis"},{"key":"BFaps201542_CR26","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1535-7163.MCT-06-0478","volume":"5","author":"PL Kuo","year":"2006","unstructured":"Kuo PL, Hsu YL, Cho CY . Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT\/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther 2006; 5: 3209\u201321.","journal-title":"Mol Cancer Ther"},{"key":"BFaps201542_CR27","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1074\/jbc.M601595200","volume":"281","author":"SK Sandur","year":"2006","unstructured":"Sandur SK, Ichikawa H, Sethi G, Ahn KS, Aggarwal BB . Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 2006; 281: 17023\u201333.","journal-title":"J Biol Chem"},{"key":"BFaps201542_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/aps.2013.152","volume":"35","author":"W Yan","year":"2014","unstructured":"Yan W, Wang TY, Fan QM, Du L, Xu JK, Zhai ZJ, et al. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice. Acta Pharmacol Sin 2014; 35: 124\u201334.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps201542_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4248\/BR201304007","volume":"1","author":"W Yan","year":"2013","unstructured":"Yan W, Tu B, Liu YY, Wang TY, Qiao H, Zhai ZJ, et al. Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions. Bone Res 2013; 1: 362\u201370.","journal-title":"Bone Res"},{"key":"BFaps201542_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrc1528","volume":"5","author":"CJ Logothetis","year":"2005","unstructured":"Logothetis CJ, Lin SH . Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21\u20138.","journal-title":"Nat Rev Cancer"},{"key":"BFaps201542_CR31","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/1078-0432.CCR-05-2570","volume":"12","author":"L Miele","year":"2006","unstructured":"Miele L . Notch signaling. Clin Cancer Res 2006; 12: 1074\u20139.","journal-title":"Clin Cancer Res"},{"key":"BFaps201542_CR32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2174\/156652406779010830","volume":"6","author":"L Miele","year":"2006","unstructured":"Miele L, Golde T, Osborne B . Notch signaling in cancer. Curr Mol Med 2006; 6: 905\u201318.","journal-title":"Curr Mol Med"},{"key":"BFaps201542_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1476-4598-8-35","volume":"8","author":"N Chadwick","year":"2009","unstructured":"Chadwick N, Zeef L, Portillo V, Fennessy C, Warrander F, Hoyle S, et al. Identification of novel Notch target genes in T cell leukaemia. Mol Cancer 2009; 8: 35.","journal-title":"Mol Cancer"},{"key":"BFaps201542_CR34","first-page":"779","volume":"14","author":"C Parr","year":"2004","unstructured":"Parr C, Watkins G, Jiang WG . The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004; 14: 779\u201386.","journal-title":"Int J Mol Med"},{"key":"BFaps201542_CR35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1078-0432.CCR-08-1631","volume":"15","author":"B Bin Hafeez","year":"2009","unstructured":"Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 2009; 15: 452\u20139.","journal-title":"Clin Cancer Res"},{"key":"BFaps201542_CR36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jcb.22451","volume":"109","author":"Z Wang","year":"2010","unstructured":"Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 2010; 109: 726\u201336.","journal-title":"J Cell Biochem"},{"key":"BFaps201542_CR37","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","volume":"16","author":"T Yoneda","year":"2001","unstructured":"Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R . A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486\u201395.","journal-title":"J Bone Miner Res"},{"key":"BFaps201542_CR38","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1158\/0008-5472.CAN-04-4458","volume":"65","author":"JT Price","year":"2005","unstructured":"Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65: 4929\u201338.","journal-title":"Cancer Res"},{"key":"BFaps201542_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13048-014-0078-2","volume":"7","author":"C Yan","year":"2014","unstructured":"Yan C, Zhu Y, Zhang X, Chen X, Zheng W, Yang J . Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cells. J Ovarian Res 2014; 7: 78.","journal-title":"J Ovarian Res"},{"key":"BFaps201542_CR40","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1080\/10428190802353591","volume":"49","author":"TC Chou","year":"2008","unstructured":"Chou TC . Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008; 49: 2059\u201380.","journal-title":"Leuk Lymphoma"},{"key":"BFaps201542_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"BFaps201542_CR42","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","volume":"10","author":"L Zhao","year":"2004","unstructured":"Zhao L, Wientjes MG, Au JL . Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10: 7994\u20138004.","journal-title":"Clin Cancer Res"},{"key":"BFaps201542_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3892\/ol.2011.520","volume":"3","author":"QF Ye","year":"2012","unstructured":"Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY . Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett 2012; 3: 879\u201384.","journal-title":"Oncol Lett"},{"key":"BFaps201542_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/1061186X.2014.950668","volume":"23","author":"T Singh","year":"2015","unstructured":"Singh T, Kaur V, Kumar M, Kaur P, Murthy RS, Rawal RK . The critical role of bisphosphonates to target bone cancer metastasis: an overview. J Drug Target 2015; 23: 1\u201315.","journal-title":"J Drug Target"},{"key":"BFaps201542_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1128\/MCB.18.1.629","volume":"18","author":"AB Niculescu 3rd","year":"1998","unstructured":"Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI . Effects of p21 (Cip1\/Waf1) at both the G1\/S and the G2\/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18: 629\u201343.","journal-title":"Mol Cell Biol"},{"key":"BFaps201542_CR46","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/0092-8674(94)90379-4","volume":"76","author":"V Dulic","year":"1994","unstructured":"Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013\u201323.","journal-title":"Cell"},{"key":"BFaps201542_CR47","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1128\/MCB.17.8.4877","volume":"17","author":"VV Ogryzko","year":"1997","unstructured":"Ogryzko VV, Wong P, Howard BH . WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997; 17: 4877\u201382.","journal-title":"Mol Cell Biol"},{"key":"BFaps201542_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF02547227","volume":"11","author":"A Jung","year":"1973","unstructured":"Jung A, Bisaz S, Fleisch H . The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973; 11: 269\u201380.","journal-title":"Calcif Tissue Res"},{"key":"BFaps201542_CR49","first-page":"157","volume":"2","author":"HJ Tong","year":"2014","unstructured":"Tong HJ, Liu HQ, Wang YY, Yang F, Shi Q, Fernandes JC, et al. A novel in vitro system for intracellular delivery of nonviral DNA. J Orthop Transl 2014; 2: 157\u201364.","journal-title":"J Orthop Transl"},{"key":"BFaps201542_CR50","doi-asserted-by":"publisher","first-page":"10287","DOI":"10.1073\/pnas.1401337111","volume":"111","author":"A Swami","year":"2014","unstructured":"Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A 2014; 111: 10287\u201392.","journal-title":"Proc Natl Acad Sci U S A"}],"updated-by":[{"DOI":"10.1038\/s41401-019-0232-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000}}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201542","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T09:46:45Z","timestamp":1718012805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,3]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["BFaps201542"],"URL":"https:\/\/doi.org\/10.1038\/aps.2015.42","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,3]]},"assertion":[{"value":"7 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}